Biotech’s Rally Shows No Signs of Slowing Down: Today’s Reports on Eyegate Pharmaceuticals and VIVUS

NEW YORK, NY / ACCESSWIRE / February 22, 2017 /
The Biotech Industry’s rally does not appear to be losing any steam in 2016. Both the iShares NASDAQ Biotechnology Index ETF and the SPDR S&P Biotech ETF have just posted four consecutive weekly gains, the first time since August 2016 (iShares) and June 2016 (SPDR). While President Trump has also commented on high drug prices, the landscape appears to be easing for the industry in 2017 as Trump has also promised to speed up the FDA’s approval process and has promised a “phenomenal” tax plan for American businesses, although the market is still awaiting detailed announcements.

Additionally, the industry has seen a number of mergers and acquisition deals already completed this year. In January, Takeda Pharmaceutical announced a deal to acquire Ariad for $24.00 per share in cash, or approximately $5.2 billion, a premium of roughly 75 percent. The amount of M&A deals is expected to pick up rapidly in 2017 as major drug makers look to boost up revenues.

“2017 is likely to push biopharma deal making to new heights,” wrote Ernst & Young’s Andrew Forman, in a research note titled M&A Outlook and Firepower Report 2017.

“Large drug companies have been making money doing things that are artificial and unsustainable. Like price increases, inversions and financial engineering,” says Brad Loncar, a cancer-company expert at Loncar Investments. “Because those things are coming to an end and the environment for the pharma industry is becoming much more challenging, companies are having a real problem posting revenue growth,” says Loncar. “The only way they can get revenue growth is to buy it.”

Let’s Take a
Closer Look at Today’s Trending Tickers

Eyegate Pharmaceuticals’ shares soared 125.62 percent to close at $3.70 a share on Tuesday. The stock traded between $2.13 and $3.90 on volume of 29.78 million shares traded. The company has entered into an exclusive, worldwide licensing agreement with a subsidiary of Valeant Pharmaceuticals International for the commercialization and manufacturing rights to the EyeGate® II Delivery System and EGP-437 combination product candidate for the treatment of post-operative pain and inflammation in ocular surgery patients.

“This second licensing agreement with Valeant provides an important validation of both the clinical and commercial potential of iontophoretic EGP-437. We believe that Bausch + Lomb’s sales, marketing and commercial capabilities in ophthalmology are unrivalled, making them the optimal partner to bring this unique product to market,” said Stephen From, President and Chief Executive Officer of EyeGate.

Access Today’s Eyegate Pharmaceuticals
Research Report Click Here

VIVUS’ shares gained 0.92 percent to close at $1.10 a share on Tuesday. The stock traded between $1.08 and $1.11 on volume 287,406 million shares traded. On January 9th, the company acquired the exclusive, worldwide rights for the development and commercialization of tacrolimus and ascomycin for the treatment of Pulmonary Arterial Hypertension (PAH) and related vascular diseases from Selten Pharma, Inc.

“Pulmonary Arterial Hypertension is a degenerative disease with current treatment options that only address the symptoms to slow the progression of the disease. We are excited about the potential of tacrolimus and ascomycin to significantly improve the quality of life and life expectancy of PAH patients,” said Seth H. Z. Fischer, VIVUS’ Chief Executive Officer. “The move into PAH is the latest announcement in our efforts to reshape VIVUS to build long-term stockholder value, and we look forward to additional announcements in the future.”

Access Today’s VIVUS Research Report Click
Here

Today’s Features Includes:

Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG)

VIVUS, Inc. (NASDAQ: VVUS)

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address: Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email: contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 455698

Go Top